{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:32:23Z","timestamp":1791955943873,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s13300-024-01546-1","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T04:02:54Z","timestamp":1708056174000},"page":"741-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Menopausal Hormone Therapy in Women with Type 2 Diabetes Mellitus: An Updated Review"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-1376","authenticated-orcid":false,"given":"Stavroula A.","family":"Paschou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0811-8156","authenticated-orcid":false,"given":"Kleoniki I.","family":"Athanasiadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-785X","authenticated-orcid":false,"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"1546_CR1","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.2337\/db16-0766","volume":"66","author":"R Unnikrishnan","year":"2017","unstructured":"Unnikrishnan R, Pradeepa R, Joshi SR, Mohan V. Type 2 diabetes: demystifying the global epidemic. Diabetes. 2017;66:1432\u201342.","journal-title":"Diabetes"},{"key":"1546_CR2","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1530\/REP-21-0022","volume":"162","author":"SU Park","year":"2021","unstructured":"Park SU, Walsh L, Berkowitz KM. Mechanisms of ovarian aging. Reproduction. 2021;162:R19-33.","journal-title":"Reproduction"},{"key":"1546_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.maturitas.2021.12.001","volume":"158","author":"M Rees","year":"2022","unstructured":"Rees M, Abernethy K, Bachmann G, et al. The essential menopause curriculum for healthcare professionals: a European Menopause and Andropause Society (EMAS) position statement. Maturitas. 2022;158:70\u20137.","journal-title":"Maturitas"},{"key":"1546_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2174\/1570161116666180625124405","volume":"17","author":"S\u0391 Paschou","year":"2019","unstructured":"Paschou S\u0391, Anagnostis P, Pavlou DI, Vryonidou A, Goulis DG, Lambrinoudaki I. Diabetes in menopause: risks and management. Curr Vasc Pharmacol. 2019;17:556\u201363.","journal-title":"Curr Vasc Pharmacol"},{"key":"1546_CR5","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/GME.0000000000001136","volume":"25","author":"J Hallajzadeh","year":"2018","unstructured":"Hallajzadeh J, Khoramdad M, Izadi N, et al. Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies. Menopause. 2018;25:1155\u201364.","journal-title":"Menopause"},{"key":"1546_CR6","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1097\/CORR.0000000000000867","volume":"477","author":"SA Lozano Calder\u00f3n","year":"2019","unstructured":"Lozano Calder\u00f3n SA, Garbutt C, et al. Clinical and molecular analysis of pathologic fracture-associated osteosarcoma: microRNA profile is different and correlates with prognosis. Clin Orthop Relat Res. 2019;477:2114\u201326.","journal-title":"Clin Orthop Relat Res."},{"key":"1546_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.crwh.2018.e00056","volume":"18","author":"S\u0391 Paschou","year":"2018","unstructured":"Paschou S\u0391, Anagnostis P, Goulis DG, Lambrinoudaki I. Diet and lifestyle for post-reproductive health: focus on diabetes. Case Rep Women\u2019s Health. 2018;18: e00056.","journal-title":"Case Rep Women\u2019s Health"},{"issue":"12","key":"1546_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/01.hjr.0000186617.29992.11","volume":"3","author":"T Thomsen","year":"2005","unstructured":"Thomsen T. HeartScore\u00ae: a new web-based approach to European cardiovascular disease risk management. Eur J Cardiovasc Prev Rehabil. 2005;3(12):424\u20136.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"1546_CR9","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","volume":"78","author":"SS Virani","year":"2021","unstructured":"Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia. J Am Coll Cardiol. 2021;78:960\u201393.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1546_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/13697137.2023.2184252","volume":"26","author":"PS Cerdas","year":"2023","unstructured":"Cerdas PS. Menopause and diabetes. Climacteric. 2023;26(3):216\u201321.","journal-title":"Climacteric"},{"key":"1546_CR11","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s13300-019-00695-y","volume":"10","author":"SA Paschou","year":"2019","unstructured":"Paschou SA, Papanas N. Type 2 diabetes mellitus and menopausal hormone therapy: an update. Diabetes Ther. 2019;10:2313\u201320.","journal-title":"Diabetes Ther"},{"key":"1546_CR12","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1210\/jc.2003-030242","volume":"88","author":"MC Carr","year":"2003","unstructured":"Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404\u201311.","journal-title":"J Clin Endocrinol Metab"},{"key":"1546_CR13","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41574-022-00708-0","volume":"18","author":"I Lambrinoudaki","year":"2022","unstructured":"Lambrinoudaki I, Paschou SA, Armeni E, Goulis DG. The interplay between diabetes mellitus and menopause: clinical implications. Nat Rev Endocrinol. 2022;18:608\u201322.","journal-title":"Nat Rev Endocrinol"},{"key":"1546_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1530\/EJE-18-0602","volume":"180","author":"P Anagnostis","year":"2019","unstructured":"Anagnostis P, Christou K, Artzouchaltzi A-M, et al. Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. Eur J Endocrinol. 2019;180:41\u201350.","journal-title":"Eur J Endocrinol"},{"key":"1546_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/13697137.2017.1386649","volume":"20","author":"D Pu","year":"2017","unstructured":"Pu D, Tan R, Yu Q, Wu J. Metabolic syndrome in menopause and associated factors: a meta-analysis. Climacteric. 2017;20:583\u201391.","journal-title":"Climacteric"},{"key":"1546_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2337\/dc13-1986","volume":"37","author":"D Appiah","year":"2014","unstructured":"Appiah D, Winters SJ, Hornung CA. Bilateral oophorectomy and the risk of incident diabetes in postmenopausal women. Diabetes Care. 2014;37:725\u201333.","journal-title":"Diabetes Care"},{"key":"1546_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/obr.13605","volume":"24","author":"S Weidlinger","year":"2023","unstructured":"Weidlinger S, Winterberger K, Pape J, et al. Impact of estrogens on resting energy expenditure: a systematic review. Obes Rev. 2023;24:10.","journal-title":"Obes Rev"},{"key":"1546_CR18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/ijo.2008.25","volume":"32","author":"JC Lovejoy","year":"2008","unstructured":"Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes. 2008;32:949\u201358.","journal-title":"Int J Obes"},{"key":"1546_CR19","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s11255-022-03392-1","volume":"55","author":"ND Karakousis","year":"2023","unstructured":"Karakousis ND, Biliou S, Pyrgioti EE, Georgakopoulos PN, Liakopoulos V, Papanas N. Frailty, sarcopenia and diabetic kidney disease: where do we stand? Int Urol Nephrol. 2023;55:1173\u201381.","journal-title":"Int Urol Nephrol"},{"key":"1546_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.682012","author":"A Geraci","year":"2021","unstructured":"Geraci A, Calvani R, Ferri E, Marzetti E, Arosio B, Cesari M. Sarcopenia and menopause: the role of estradiol. Front Endocrinol (Lausanne). 2021. https:\/\/doi.org\/10.3389\/fendo.2021.682012.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1546_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.maturitas.2018.04.005","volume":"115","author":"SA Paschou","year":"2018","unstructured":"Paschou SA, Anagnostis P, Goulis DG, Lambrinoudaki I. Androgen excess and post-reproductive health. Maturitas. 2018;115:115\u20136.","journal-title":"Maturitas"},{"key":"1546_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1089\/met.2017.0128","volume":"16","author":"R de Mutsert","year":"2018","unstructured":"de Mutsert R, Gast K, Widya R, et al. Associations of abdominal subcutaneous and visceral fat with insulin resistance and secretion differ between men and women: the Netherlands epidemiology of obesity study. Metab Syndr Relat Disord. 2018;16:54\u201363.","journal-title":"Metab Syndr Relat Disord"},{"key":"1546_CR23","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/humrep\/dev054","volume":"30","author":"JS Brand","year":"2015","unstructured":"Brand JS, Onland-Moret NC, Eijkemans MJC, et al. Diabetes and onset of natural menopause: results from the European prospective investigation into cancer and nutrition. Hum Reprod. 2015;30:1491\u20138.","journal-title":"Hum Reprod"},{"key":"1546_CR24","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1007\/s00125-009-1456-y","volume":"52","author":"B de Lauzon-Guillain","year":"2009","unstructured":"de Lauzon-Guillain B, Fournier A, Fabre A, et al. Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle G\u00e9n\u00e9rale de l\u2019Education Nationale (E3N) cohort. Diabetologia. 2009;52:2092\u2013100.","journal-title":"Diabetologia"},{"issue":"13","key":"1546_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/1753-0407.13129","volume":"2","author":"S Tatulashvili","year":"2021","unstructured":"Tatulashvili S, Gusto G, Cosson E, et al. Gonadal hormonal factors before menopause and incident type 2 diabetes in women: a 22-year follow-up of 83 799 women from the E3N cohort study. J Diabetes. 2021;2(13):330\u20138.","journal-title":"J Diabetes"},{"key":"1546_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/GME.0000000000000714","volume":"24","author":"ES LeBlanc","year":"2017","unstructured":"LeBlanc ES, Kapphahn K, Hedlin H, et al. Reproductive history and risk of type 2 diabetes mellitus in postmenopausal women: findings from the Women\u2019s Health Initiative. Menopause. 2017;24:64\u201372.","journal-title":"Menopause"},{"key":"1546_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.maturitas.2022.01.001","volume":"159","author":"SR Mishra","year":"2022","unstructured":"Mishra SR, Waller M, Chung H-F, Mishra GD. Association between reproductive lifespan and risk of incident type 2 diabetes and hypertension in postmenopausal women: findings from a 20-year prospective study. Maturitas. 2022;159:52\u201361.","journal-title":"Maturitas"},{"key":"1546_CR28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/dme.13301","volume":"34","author":"SK Park","year":"2017","unstructured":"Park SK, Harlow SD, Zheng H, et al. Association between changes in oestradiol and follicle-stimulating hormone levels during the menopausal transition and risk of diabetes. Diabet Med. 2017;34:531\u20138.","journal-title":"Diabet Med"},{"key":"1546_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.annepidem.2021.02.011","volume":"58","author":"AN Reeves","year":"2021","unstructured":"Reeves AN, Elliott MR, Brooks MM, et al. Symptom clusters predict risk of metabolic-syndrome and diabetes in midlife: the study of women\u2019s health across the nation. Ann Epidemiol. 2021;58:48\u201355.","journal-title":"Ann Epidemiol"},{"key":"1546_CR30","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1463-1326.2005.00545.x","volume":"8","author":"SR Salpeter","year":"2006","unstructured":"Salpeter SR, Walsh JME, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8:538\u201354.","journal-title":"Diabetes Obes Metab"},{"key":"1546_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.maturitas.2018.12.012","volume":"121","author":"J-E Kim","year":"2019","unstructured":"Kim J-E, Choi J, Park J, et al. Associations of postmenopausal hormone therapy with metabolic syndrome among diabetic and non-diabetic women. Maturitas. 2019;121:76\u201382.","journal-title":"Maturitas"},{"key":"1546_CR32","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00125-004-1448-x","volume":"47","author":"KL Margolis","year":"2004","unstructured":"Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women\u2019s Health Initiative Hormone Trial. Diabetologia. 2004;47:1175\u201387.","journal-title":"Diabetologia"},{"key":"1546_CR33","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","volume":"388","author":"H Wang","year":"2016","unstructured":"Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459\u2013544.","journal-title":"Lancet"},{"key":"1546_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101575","volume":"35","author":"A Brennan","year":"2021","unstructured":"Brennan A, Rees M. Menopausal hormone therapy in women with benign gynaecological conditions and cancer. Best Pract Res Clin Endocrinol Metab. 2021;35: 101575.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1546_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1080\/13697137.2016.1187123","volume":"19","author":"P Stute","year":"2016","unstructured":"Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric. 2016;19:316\u201328.","journal-title":"Climacteric"},{"key":"1546_CR36","first-page":"13","volume":"8","author":"P Chen","year":"2022","unstructured":"Chen P, Li B, Ou-Yang L. Role of estrogen receptors in health and disease. Front Endocrinol (Lausanne). 2022;8:13.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1546_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101561","volume":"35","author":"E Armeni","year":"2021","unstructured":"Armeni E, Paschou SA, Goulis DG, Lambrinoudaki I. Hormone therapy regimens for managing the menopause and premature ovarian insufficiency. Best Pract Res Clin Endocrinol Metab. 2021;35: 101561.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1546_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.maturitas.2020.11.004","volume":"147","author":"I Lambrinoudaki","year":"2021","unstructured":"Lambrinoudaki I, Paschou SA, Lumsden MA, et al. Premature ovarian insufficiency: a toolkit for the primary care physician. Maturitas. 2021;147:53\u201363.","journal-title":"Maturitas"},{"key":"1546_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.maturitas.2018.08.009","volume":"117","author":"R Slopien","year":"2018","unstructured":"Slopien R, Wender-Ozegowska E, Rogowicz-Frontczak A, et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6\u201310.","journal-title":"Maturitas"},{"key":"1546_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.maturitas.2019.05.003","volume":"126","author":"SA Paschou","year":"2019","unstructured":"Paschou SA, Marina LV, Spartalis E, et al. Therapeutic strategies for type 2 diabetes mellitus in women after menopause. Maturitas. 2019;126:69\u201372.","journal-title":"Maturitas"},{"key":"1546_CR41","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/GME.0000000000000847","volume":"24","author":"RJ Santen","year":"2017","unstructured":"Santen RJ. Use of cardiovascular age for assessing risks and benefits of menopausal hormone therapy. Menopause. 2017;24:589\u201395.","journal-title":"Menopause"},{"key":"1546_CR42","first-page":"8","volume":"2015","author":"HM Boardman","year":"2015","unstructured":"Boardman HM, Hartley L, Eisinga A, Main C, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;2015:8.","journal-title":"Cochrane Database Syst Rev"},{"key":"1546_CR43","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/humupd\/dmy039","volume":"25","author":"C Oliver-Williams","year":"2019","unstructured":"Oliver-Williams C, Glisic M, Shahzad S, et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum Reprod Update. 2019;25:257\u201371.","journal-title":"Hum Reprod Update"},{"key":"1546_CR44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.thromres.2018.06.014","volume":"168","author":"D Rovinski","year":"2018","unstructured":"Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. Thromb Res. 2018;168:83\u201395.","journal-title":"Thromb Res"},{"key":"1546_CR45","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1097\/GME.0000000000001848","volume":"28","author":"J-E Kim","year":"2021","unstructured":"Kim J-E, Choi J, Park J, Shin A, Choi N-K, Choi J-Y. Effects of menopausal hormone therapy on cardiovascular diseases and type 2 diabetes in middle-aged postmenopausal women: analysis of the Korea National Health Insurance Service Database. Menopause. 2021;28:1225\u201332.","journal-title":"Menopause"},{"key":"1546_CR46","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/GME.0000000000001033","volume":"25","author":"KE Gray","year":"2018","unstructured":"Gray KE, Katon JG, LeBlanc ES, et al. Vasomotor symptom characteristics: are they risk factors for incident diabetes? Menopause. 2018;25:520\u201330.","journal-title":"Menopause"},{"key":"1546_CR47","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3109\/13697137.2013.798272","volume":"16","author":"A Monterrosa-Castro","year":"2013","unstructured":"Monterrosa-Castro A, Bl\u00fcmel JE, Portela-Buelvas K, et al. Type II diabetes mellitus and menopause: a multinational study. Climacteric. 2013;16:663\u201372.","journal-title":"Climacteric"},{"key":"1546_CR48","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S2213-8587(22)00076-6","volume":"10","author":"RE Nappi","year":"2022","unstructured":"Nappi RE, Chedraui P, Lambrinoudaki I, Simoncini T. Menopause: a cardiometabolic transition. Lancet Diabetes Endocrinol. 2022;10:442\u201356.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01546-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-024-01546-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01546-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T06:36:38Z","timestamp":1710830198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-024-01546-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1546"],"URL":"https:\/\/doi.org\/10.1007\/s13300-024-01546-1","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"7 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nikolaos Papanas is a member of the Editorial Board for Diabetes Therapy. Nikolaos Papanas was not involved in the selection for peer reviewers for the manuscript, not any of the subsequent editorial decisions. Stavroula A. Paschou has participated in clinical trials sponsored by Novo Nordisk, Sanofi, and Eli Lilly, and has received honoraria for advisory board membership or lectures from Novo Nordisk, Sanofi, Bausch Health, and Abbott. Kleoniki I. Athanasiadou has no conflict of interest. Nikolaos Papanas has been an advisory board member of TrigoCare International, Abbott, AstraZeneca, Elpen, MSD, Novartis, Novo Nordisk, Sanofi-Aventis and Takeda; has participated in sponsored studies by Eli Lilly, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; received honoraria as a speaker for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elpen, Galenica, MSD, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, Takeda and Vianex; and attended conferences sponsored by TrigoCare International, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Pfizer, and Sanofi-Aventis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}